{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:07Z","timestamp":1753891987366,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Impetigo is the most common childhood skin infection in the world. There are two patterns of impetigo: <jats:italic>nonbullous<\/jats:italic> (or impetigo contagiosa) and <jats:italic>bullous<\/jats:italic>. The <jats:italic>nonbullous<\/jats:italic> type is due to <jats:italic>Staphylococcus aureus<\/jats:italic> and group A beta-haemolytic <jats:italic>Streptococcus<\/jats:italic> and occurs in 70% of impetigo cases. Impetigo is often a self-limited disease, but complications can sometimes occur. Therapy depends on the extent and site of the lesions and on the presence of systemic symptoms. The increase in multidrug resistance pathogens, such as methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic>, mupirocin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> or quinolone-resistant <jats:italic>Staphylococcus aureus<\/jats:italic>, requires the development of new antibiotics against these agents. The aim of this review is to evaluate the efficacy and safety of ozenoxacin in children compared to those of other approved topical antimicrobial therapies. The bactericidal activity against both susceptible and resistant organisms is a relevant feature of ozenoxacin because the bacterial strain and potential for resistance are generally not known at the beginning of therapy. Additionally, its minimal dermal absorption and its capability to reach high concentrations in the upper layers of the epidermidis agrees with the recommended practice aimed at avoiding the emergence of bacterial resistance in presence of a good safety profile. Further studies with real-life analyses and pharmacoeconomic evaluation are needed to confirm its role as first-line and second-line therapy in children with impetigo.<\/jats:p>","DOI":"10.3389\/fphar.2020.559708","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T10:31:38Z","timestamp":1605695498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety"],"prefix":"10.3389","volume":"11","author":[{"given":"Giusy","family":"Davino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"D\u2019Alvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","article-title":"The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma","volume":"10","author":"Bowen","year":"2015","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-4362.2003.01647.x","article-title":"Impetigo: an update","volume":"42","author":"Brown","year":"2003","journal-title":"Int. J. Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/fmb-2017-0289","article-title":"Comparative in vitro antibacterial activity of ozenoxacin against gram-positive clinical isolates","volume":"13","author":"Canton","year":"2018","journal-title":"Future Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/fmb-2017-0289","article-title":"Diagnosis and treatment of impetigo","volume":"75","author":"Cole","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"B5","unstructured":"2014"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fmb-2017-0291","article-title":"Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs","volume":"13","author":"Gonz\u00e1lez Borroto","year":"2018","journal-title":"Future Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fmb.14.78","article-title":"Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial","volume":"9","author":"Gropper","year":"","journal-title":"Future Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1080\/14787210.2019.1573671","article-title":"Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo","volume":"9","author":"Gropper","year":"","journal-title":"Future Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-4362.2003.01647.x","article-title":"Impetigo: diagnosis and treatment","volume":"90","author":"Hartman-Adams","year":"2014","journal-title":"Am. Fam. Physician"},{"key":"B10","unstructured":"Ozanex (ozenoxacin) 1% cream. Product monograph. Ferrer internacional2016"},{"key":"B11","unstructured":"Ozanex (ozenoxacin) 1% cream. Product monograph. Ferrer internacional2017"},{"volume-title":"Nelson textbook of pediatrics","year":"2011","author":"Kliegman","key":"B12"},{"article-title":"Effect of the overexpression of the efflux pumps MepA and NorA from Staphylococcus aureus in the resistance to ozenoxacin and other quinolones","year":"2018","author":"L\u00f3pez Cubillos","key":"B13"},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3928\/0090-4481-20000101-07","article-title":"Bacterial skin infections in children: the common and the not so common","volume":"29","author":"Mancini","year":"2000","journal-title":"Pediatr. Ann."},{"key":"B15","unstructured":"2017"},{"key":"B16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/jac\/49.3.455","article-title":"Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial","volume":"154","author":"Rosen","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/0090-4481-20000101-07","article-title":"Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus","volume":"13","author":"Tarrag\u00f3","year":"2018","journal-title":"Future Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000504536","article-title":"Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents","volume":"236","author":"Torrelo","year":"2020","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/fmb.14.78","article-title":"Ozenoxacin: a review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B20","unstructured":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/fmb.14.85","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.559708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T20:23:33Z","timestamp":1607372613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.559708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":21,"alternative-id":["10.3389\/fphar.2020.559708"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.559708","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"article-number":"559708"}}